Nexalin Technology

Nexalin Technology Current Assets

The Current Assets of Nexalin Technology (NXL) as of Nov 11, 2026 is 4.22 M USD. In the previous year, Current Assets was 3.96 M USD — a change of 6.48% (higher).

Current Assets

4.22 MUSD

YoY

6.48%

Last updated:

Current Assets of Nexalin Technology is 2025 4.22 M USD. Current Assets of Nexalin Technology was 2024 3.96 M USD. It decreases by 6.48% higher compared to the previous year.

The Nexalin Technology Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
111,159.00 USD
Jan 1, 2020
116,886.00 USD
Jan 1, 2021
752,656.00 USD
Jan 1, 2022
7.43 M USD
Jan 1, 2023
3.43 M USD
Jan 1, 2024
3.96 M USD
Jan 1, 2025
4.22 M USD
The Nexalin Technology Current Assets history
YEARCurrent AssetsYoY
4.22 MUSD+6.48%
3.96 MUSD+15.49%
3.43 MUSD-53.81%
7.43 MUSD+886.57%
752,656.00USD+543.92%
116,886.00USD+5.15%
111,159.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nexalin Technology Stock analysis

What does Nexalin Technology do? Nexalin Technology, Inc. generates revenue through the sale of its neurostimulation products, specifically the Generation 1 or Gen-1 device, which treats anxiety and insomnia using bioelectronic medical technology without drugs or psychotherapy. The company's products are non-invasive and undetectable, targeting individuals with mental health issues seeking relief without adverse side effects. Nexalin designs clinical trials for Gen-2, aimed at treating substance use disorders, particularly opiate-related issues, chronic pain, Alzheimer’s disease, and dementia, though Gen-2 is not yet commercially available. The firm focuses on medical applications where traditional treatments may be less effective or carry risks. The primary buyers of Gen-1 are patients with anxiety and insomnia who prefer non-pharmacological solutions. The company’s marketing emphasizes the device’s ease of administration and lack of side effects, appealing to those dissatisfied with conventional treatments. Nexalin’s clinical trials for Gen-2 target healthcare providers and institutions treating substance use disorders, Alzheimer’s, and dementia, positioning the product for future market entry in these high-demand segments. The firm’s revenue model relies on direct sales of Gen-1 and anticipated future sales of Gen-2 once clinical trials are completed and regulatory approvals are secured. Nexalin’s products operate through a unique waveform technology that combines varying voltages, currents, electromagnetic fields, and frequencies applied via electrodes on the head. This technology differentiates the company in the medical device market by offering a non-invasive alternative to drug-based therapies. The company’s focus on mental health and neurological conditions aligns with growing demand for innovative, side-effect-free treatments, enabling it to target specific patient segments seeking alternatives to traditional pharmaceuticals. Nexalin Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nexalin Technology stock

Current Assets of Nexalin Technology is 4.22 M USD in 2025.

Current Assets of Nexalin Technology changed from 3.96 M USD to 4.22 M USD, representing a 6.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Nexalin Technology since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Nexalin Technology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Nexalin Technology

All Key Metrics — Nexalin Technology